Tag: Abstract

news source FOR company information content 1 market releases

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation

Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing...

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

Amorepacific Museum of Art Presents Mark Bradford: Keep Walking

First Major Solo Exhibition in Korea by Mark Bradford to Open at Amorepacific Museum of ArtPioneer of 'Social Abstraction' Unveiled in Landmark Exhibition in...

Amorepacific Museum of Art Presents Mark Bradford: Keep Walking

First Major Solo Exhibition in Korea by Mark Bradford to Open at Amorepacific Museum of ArtPioneer of 'Social Abstraction' Unveiled in Landmark Exhibition in...

Amorepacific Museum of Art Presents Mark Bradford: Keep Walking

First Major Solo Exhibition in Korea by Mark Bradford to Open at Amorepacific Museum of ArtPioneer of 'Social Abstraction' Unveiled in Landmark Exhibition in...

Amorepacific Museum of Art Presents Mark Bradford: Keep Walking

First Major Solo Exhibition in Korea by Mark Bradford to Open at Amorepacific Museum of ArtPioneer of 'Social Abstraction' Unveiled in Landmark Exhibition in...

Amorepacific Museum of Art Presents Mark Bradford: Keep Walking

First Major Solo Exhibition in Korea by Mark Bradford to Open at Amorepacific Museum of ArtPioneer of 'Social Abstraction' Unveiled in Landmark Exhibition in...

Dark Reset: Survival Before the Silence – Former Pentagon Insider Warns of 2025 Collapse Plan and America’s Final Signal

As the world fixates on cyber warfare, grid instability, and rising tensions in the Middle East, a quieter alarm is sounding beneath the headlines. It doesn’t come from mainstream media, but from former defense insiders and everyday Americans quietly preparing for a different kind of threat — one that won’t announce itself with sirens or headlines. That’s the driving force behind Dark Reset: Survival Before the Silence, a civilian resilience system based on the belief that the next collapse won’t start with fire — it’ll start with silence.

As the world fixates on cyber warfare, grid instability, and rising tensions in the Middle East, a quieter alarm is sounding beneath the headlines. It doesn’t come from mainstream media, but from former defense insiders and everyday Americans quietly preparing for a different kind of threat — one that won’t announce itself with sirens or headlines. That’s the driving force behind Dark Reset: Survival Before the Silence, a civilian resilience system based on the belief that the next collapse won’t start with fire — it’ll start with silence.

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH, Aug. 1, 2025 /PRNewswire/...

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025

SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data” at the Alzheimer’s Association International Conference 2025 (“AAIC 2025”) held in Toronto, Canada and online from July 27-31, 2025.

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey.

- A word from our sponsors -

HomeTagsAbstract